HEMGENIX
Active Ingredient: ETRANACOGENE DEZAPARVOVEC
Product Overview
About HEMGENIX
HEMGENIX is a gene therapy treatment designed to address beta-thalassemia, a genetic disorder affecting the production of hemoglobin in the blood. This innovative medicine utilizes the active ingredient ETRANACOGENE DEZAPARVOVEC to provide a novel approach to managing this condition.
Key Benefits & Uses
- Treatment of beta-thalassemia, a genetic disorder affecting hemoglobin production in the blood.
- May help increase hemoglobin levels and reduce the need for frequent blood transfusions.
- Administered via a single infusion, providing a long-term solution for patients with beta-thalassemia.
Active Ingredient & Action
ETRANACOGENE DEZAPARVOVEC is a gene therapy vector that works by delivering a healthy copy of the beta-globin gene to the patient's bone marrow cells. This enables the production of functional hemoglobin, helping to alleviate the symptoms of beta-thalassemia.
Important Notes
HEMGENIX is a prescription medicine and should only be administered under the guidance of a qualified healthcare professional. Patients with beta-thalassemia should discuss the potential benefits and risks of HEMGENIX with their doctor to determine if this treatment is suitable for their individual needs.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.